Immunotherapy plus chemo shows promise for pancreatic cancer before surgery
NCT ID NCT06177522
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding the immunotherapy drug adebrelimab to standard chemotherapy can help shrink pancreatic tumors before surgery. About 30 people with resectable pancreatic cancer will receive the combination, and researchers will measure how many tumors are completely removed and how safe the treatment is. The goal is to improve outcomes for this aggressive cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Adebrelimab (an immunotherapy drug) combined with chemotherapy (albumin-bound paclitaxel and gemcitabine)
What this could lead to
If successful, this could offer a more effective pre-surgery treatment to shrink pancreatic tumors and improve complete removal rates.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply widely. Immunotherapy can cause immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wang Sizhen
Nanjing, Jiangsu, China
Contact Phone: •••-•••-••••